What is Complement Therapeutics?
Complement Therapeutics is a biotechnology firm dedicated to pioneering new treatments by harnessing insights from the Complement System. The company's research focuses on addressing critical unmet needs in conditions such as age-related macular degeneration and other diseases linked to complement dysregulation. By employing its advanced, patented research and world-leading expertise, Complement Therapeutics is developing innovative therapeutic modalities, including AAV gene therapies and protein-based treatments. Its lead asset, CTx001, is currently in pre-clinical development for Geographic Atrophy, a significant indication within the ophthalmology space.
How much funding has Complement Therapeutics raised?
Complement Therapeutics has raised a total of $84.7M across 2 funding rounds:
Angel/Seed
$5.7M
Series A
$79M
Angel/Seed (2022): $5.7M with participation from BGV (BioGeneration Ventures and Forbion
Series A (2023): $79M led by Generate BioVentures, Forbion, Cambridge Innovation Capital, Panakes Partners, Seroba Life Sciences Management, Gimv, and Hadean Ventures
Key Investors in Complement Therapeutics
Generate BioVentures
Generate BioVentures is a venture capital firm specializing in synthetic biology and genetic engineering, supporting research and development in genomics and molecular biology.
Forbion
Forbion is a global life sciences venture capital firm that invests in innovative therapeutics companies across all stages of pharmaceutical drug development, with a focus on Europe and North America.
Cambridge Innovation Capital
Cambridge Innovation Capital is a venture investor focused on supporting entrepreneurs in life sciences and deep tech within the Cambridge ecosystem, providing financial backing and expert guidance.
What's next for Complement Therapeutics?
The substantial enterprise-level funding and recent strategic investment indicate that Complement Therapeutics is likely in a growth or scaling phase, poised to advance its lead asset through critical development milestones. This capital infusion will be instrumental in progressing CTx001 through pre-clinical studies and potentially into clinical trials. The company's focus on gene therapy and protein-based treatments positions it at the forefront of innovation in the complement-driven disease landscape. Future strategic partnerships or further financing rounds may be anticipated as the company moves towards broader therapeutic applications and market entry.
See full Complement Therapeutics company page
